Core Points - A jury trial against Isomedix Operations, Inc., a subsidiary of STERIS plc, ended in a mistrial on January 17, 2025, after being ongoing since December 4, 2024 [1][2] - The case involves claims of personal injury due to ethylene oxide emissions from a sterilization facility in Waukegan, Illinois, which Isomedix operated from 2005 to 2008 [2] - The court will schedule a re-trial at a later date following the mistrial declaration [2] Company Actions - Isomedix plans to vigorously defend against the allegations related to ethylene oxide operations and emissions from the Waukegan facility [3] - The company has invested in its facilities and implemented processes that meet or exceed applicable environmental regulatory standards [3] Company Overview - STERIS is a leading global provider of products and services focused on infection prevention and patient care [4] - The company emphasizes creating a healthier and safer world through innovative healthcare and life sciences products and services [4]

STERIS (STE) new acquisitions and partnerships have been strengthening its product offerings. However, macroeconomic challenges continue to dampen growth. The stock carries a Zacks Rank #3 (Hold).Factors Driving STERIS' GrowthSTERIS frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses. In recent years, the company has made several large acquisitions. It purchased the surgical instrumentation, laparoscopic instrumentation and sterilization container assets f ...

STERIS plc’s (STE) growth in the fiscal second quarter of 2025 can be attributed to the robust performance of its Healthcare business. The company also benefits from the strong rebound prospects for its Applied Sterilization Technologies (“AST”) segment.Meanwhile, headwinds such as foreign currency risks and fierce competitive pressure are concerning.Year to date, shares of this Zacks Rank #3 (Hold) company have lost 2.1% against the industry’s 7.6% growth and the S&P 500’s 18.4% increase.The renowned provi ...

STERIS (STE) continues to gain from a strong rebound in procedure volumes in the United States within the Healthcare business. New acquisitions and partnerships should strengthen its product offerings. Yet macroeconomic challenges continue to dampen growth. The stock carries a Zacks Rank #3 (Hold) currently.Factors Driving STERIS' GrowthSTERIS’ Healthcare segment is gaining from the successful market adoption of its comprehensive offerings, including infection prevention consumables and capital equipment. F ...

In my previous ‘Hold’ rating on STERIS (NYSE: STE ) in September 2024, I expressed my concern about their overvalued stock price. Since then, the stock price has dropped by more than 10%, significantly underperforming the index (Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for ...

Have you evaluated the performance of Steris' (STE) international operations for the quarter ending September 2024? Given the extensive global presence of this medical products maker, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For ...

For the quarter ended September 2024, Steris (STE) reported revenue of $1.33 billion, down 1% over the same period last year. EPS came in at $2.14, compared to $2.03 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.34 billion, representing a surprise of -0.58%. The company delivered an EPS surprise of +1.42%, with the consensus EPS estimate being $2.11.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they c ...

Steris (STE) came out with quarterly earnings of $2.14 per share, beating the Zacks Consensus Estimate of $2.11 per share. This compares to earnings of $2.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.42%. A quarter ago, it was expected that this medical products maker would post earnings of $2.01 per share when it actually produced earnings of $2.03, delivering a surprise of 1%.Over the last four quarters, the company ...

Total revenue from continuing operations increased 7%; constant currency organic revenue grew 7%As reported diluted EPS from continuing operations increased to $1.51; adjusted EPS increased to $2.14Fiscal 2025 outlook reiterated DUBLIN, IRELAND, Nov. 06, 2024 (GLOBE NEWSWIRE) --  - STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 second quarter ended September 30, 2024. Total revenue from continuing operations for the second quarter of fiscal 2025 inc ...

Wall Street analysts expect Steris (STE) to post quarterly earnings of $2.11 per share in its upcoming report, which indicates a year-over-year increase of 3.9%. Revenues are expected to be $1.34 billion, down 0.4% from the year-ago quarter.Over the last 30 days, there has been a downward revision of 1.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Ah ...